Lantheus Holdings (LNTH)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$2.76 (-2.98%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Lantheus Holdings (LNTH)
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Key Insights

Critical company metrics and information
  • Share Price

    $89.73
  • Market Cap

    $6.24 Billion
  • Total Outstanding Shares

    69.53 Million Shares
  • Total Employees

    834
  • Dividend

    No dividend
  • IPO Date

    June 25, 2015
  • SIC Description

    In Vitro & In Vivo Diagnostic Substances
  • Homepage

    https://www.lantheus.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-231.48 Million
Net Cash Flow, Continuing$252.50 Million
Net Cash Flow From Financing Activities$-15.33 Million
Exchange Gains/Losses$-198,000.00
Net Cash Flow From Investing Activities$-231.48 Million
Net Cash Flow$252.30 Million
Net Cash Flow From Operating Activities$499.31 Million
Net Cash Flow From Operating Activities, Continuing$499.31 Million
Net Cash Flow From Financing Activities, Continuing$-15.33 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Earnings Per Share$6.02
Basic Earnings Per Share$6.21
Research and Development$149.60 Million
Costs And Expenses$926.64 Million
Gross Profit$969.62 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss Available To Common Stockholders, Basic$427.61 Million
Operating Expenses$489.02 Million
Income Tax Expense/Benefit$142.55 Million
Cost Of Revenue$527.18 Million
Diluted Average Shares$71.30 Million
Basic Average Shares$69.27 Million
Net Income/Loss Attributable To Parent$427.61 Million
Revenues$1.50 Billion
Net Income/Loss$427.61 Million
Other Operating Expenses$339.43 Million
Income/Loss From Continuing Operations After Tax$427.61 Million
Benefits Costs and Expenses$926.64 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations Before Tax$570.16 Million
Operating Income/Loss$480.59 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Liabilities$784.08 Million
Other Non-current Assets$410.80 Million
Assets$2.05 Billion
Wages$35.74 Million
Liabilities And Equity$2.05 Billion
Accounts Payable$44.91 Million
Noncurrent Liabilities$85.84 Million
Current Assets$1.30 Billion
Liabilities$869.92 Million
Noncurrent Assets$753.92 Million
Fixed Assets$169.51 Million
Other Current Liabilities$703.42 Million
Inventory$70.83 Million
Equity$1.18 Billion
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$1.18 Billion
Other Current Assets$1.22 Billion
Intangible Assets$173.61 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.